English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

In the recently published article “Early Prognostic Utility of Gp210 AntibodyPositive Rate in Primary Biliary Cholangitis: A Meta-Analysis”, Huang et al. summarized the published data on autoantibodies anti-gp210, one of the PBC-specific antinuclear antibodies (ANA) with a diagnostic and prognostic values in patients with primary biliary cholangitis (PBC) [1]. Anti-gp210 is indeed the major autoantibody of a family of ANAs directed against proteins of the nuclear pore complex (NPC), but it is widely accepted that the first clear-cut demonstration of the prognostic role of these PBC-specific ANAs comes from an Italian study that focused not only on anti-gp210 but also on anti-NPCs [2–4]. For completeness, we believe that it is important to inform the readers of Disease Markers also about this piece of the story.

Comment on “Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis”